Process for converting the 13-.alpha.-hydroxy group of avermectin
aglycones
    1.
    发明授权
    Process for converting the 13-.alpha.-hydroxy group of avermectin aglycones 失效
    转化阿维菌素糖苷配基的13-α-羟基的方法

    公开(公告)号:US5241083A

    公开(公告)日:1993-08-31

    申请号:US907429

    申请日:1992-07-01

    IPC分类号: C07D493/22

    CPC分类号: C07D493/22

    摘要: The natural stereochemistry at the 13-position of avermectin aglycones, normally .alpha.-oriented or below the plane of the molecule, is inverted or epimerized into the .beta.-position. The procedure starts with the avermectin aglycone compounds where the 13.alpha.-hydroxy group is activated to a mesylate leaving group. The resultant 13-.alpha.-mesylate is then displaced with a cesium carboxylate and one equivalent of the respective carboxylic acid, ending with the ester group being converted to the 13-.beta.-hydroxy configuration by transesterification in high yield.

    摘要翻译: 阿维菌素糖苷配基的13位天然立体化学,通常为α取向或低于分子平面,被倒置或差向异构化成β位。 该程序从其中13α-羟基被活化成甲磺酸酯离去基团的除虫菌素苷元化合物开始。 然后用羧酸铯和1当量相应的羧酸置换所得的13-α-甲酸盐,以酯基转移为最终,酯基以高产率转化为13-β-羟基构型。

    "> Isolation, structural elucidation and synthesis of novel antineoplastic
substances denominated
    8.
    发明授权
    Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins" 失效
    新型抗肿瘤物质的分离,结构阐释和合成,称为“考布他汀”

    公开(公告)号:US5409953A

    公开(公告)日:1995-04-25

    申请号:US832998

    申请日:1992-02-10

    CPC分类号: C07C43/23 C07D317/64

    摘要: New antineoplastic substances have been isolated, structurally elucidated and synthesized having a general structural formula of: ##STR1## wherein: R.sub.1 is OH or OCH.sub.3 ;R.sub.2 is H or OCH.sub.3 ; or R.sub.1 R.sub.2 is --OCH.sub.2 O--;R.sub.3 is H or OH;R.sub.4 is OH or OCH.sub.3.These substances have been denominated "combretastatin A-1, -A-2, -A-3, -B-1, -B-2, -B-3 and -B-4". Pharmaceutical preparation containing the substances and methods of treating a host inflicted with a neoplastic growth with the preparation is described.

    摘要翻译: 新的抗肿瘤物质已被分离,结构阐明和合成,具有以下结构式:IMA(I)或H或OCH 3; 或R1R2是-OCH2O-; R3是H或OH; R4是OH或OCH3。 这些物质被称为“考匹特他汀A-1,-A-2,-A-3,-B-1,-B-2,-B-3和-B-4”。 描述了含有用制剂对患有肿瘤生长的宿主进行处理的物质和方法的药物制剂。

    METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS
    10.
    发明申请
    METHOD OF TREATMENT USING FATTY ACID SYNTHESIS INHIBITORS 有权
    使用脂肪酸合成抑制剂治疗的方法

    公开(公告)号:US20120190747A1

    公开(公告)日:2012-07-26

    申请号:US13435130

    申请日:2012-03-30

    IPC分类号: A61K31/196 A61P3/04

    CPC分类号: A61K31/195 Y10S514/866

    摘要: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.

    摘要翻译: 本发明涉及具有脂肪酸合成抑制剂活性的天然产物,可用于治疗和预防疾病如肥胖症,癌症,糖尿病,真菌感染,结核分枝杆菌感染,疟疾感染和其他复合物原生动物疾病。